indazoles has been researched along with Fibrosarcoma in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bari, A; Caputo, F; Cerma, K; Dominici, M; Fanelli, M; Gelsomino, F; Pozzi, S | 1 |
| Chawla, S; Chmielowski, B; Dry, SM; Eckardt, MA; Eilber, FC; Higuchi, T; Hoffman, RM; Igarashi, K; Kanaya, F; Kawaguchi, K; Kiyuna, T; Li, Y; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Razmjooei, S; Russell, TA; Singh, AS; Singh, SR; Sugisawa, N; Tome, Y; Wangsiricharoen, S; Zhang, Z; Zhao, M | 1 |
| Fujihara, I; Fujita, K; Hiroma, T; Katsuyama, Y; Kitamura, R; Komori, K; Kondo, Y; Nakamura, T; Noguchi, M; Ogiso, Y; Sakashita, K; Sano, K; Yanagisawa, R | 1 |
| Araki, N; Boku, S; Goto, T; Hiraga, H; Honoki, K; Kawai, A; Matsumine, A; Nakamura, T; Nishida, Y; Sudo, A; Sugiura, H; Ueda, T; Yasuda, T; Yonemoto, T | 1 |
| Demizu, Y; Futani, H; Mohri, T; Okimoto, T; Sakagami, M; Terada, T; Tsukamoto, Y; Uwa, N | 1 |
| Chae, HJ; Kim, HR; Lee, GH | 1 |
| Alfieri, A; Kim, JH; Kim, SH; Silvestrini, B; Young, CW | 2 |
| Ara, G; Eder, JP; Herman, TS; Holden, SA; Korbut, T; Schwartz, GN; Teicher, BA | 1 |
| Hahn, GM; Ning, SC | 2 |
| Frei, E; Herman, TS; Holden, SA; Teicher, BA | 1 |
| Dezube, B; Frei, E; Herman, TS; Pardee, A; Tanaka, J; Teicher, BA | 1 |
| Epelbaum, R; Frei, E; Herman, TS; Holden, SA; Liu, SD; Teicher, BA | 1 |
| Dezube, B; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA | 1 |
1 review(s) available for indazoles and Fibrosarcoma
| Article | Year |
|---|---|
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature.
Topics: Angiogenesis Inhibitors; Fibroma; Fibrosarcoma; Humans; Indazoles; Male; Middle Aged; Polycythemia; Protein Kinase Inhibitors; Pyrimidines; Soft Tissue Neoplasms; Sulfonamides | 2021 |
14 other study(ies) available for indazoles and Fibrosarcoma
| Article | Year |
|---|---|
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fibrosarcoma; Humans; Indazoles; Irinotecan; Male; Mice, Nude; Pyrimidines; Random Allocation; Salmonella Infections; Salmonella typhimurium; Sulfonamides; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma.
Topics: Angiogenesis Inhibitors; Axilla; Drug Resistance, Neoplasm; Fibrosarcoma; Humans; Indazoles; Infant; Male; Neoadjuvant Therapy; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2016 |
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Female; Fibrosarcoma; Humans; Hypertension; Indazoles; Japan; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neurilemmoma; Pneumothorax; Product Surveillance, Postmarketing; Pyrimidines; Retrospective Studies; Sarcoma; Sarcoma, Synovial; Sulfonamides; Survival Analysis; Thrombocytopenia | 2016 |
An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: A case of myxofibrosarcoma.
Topics: Angiogenesis Inhibitors; Debridement; Fatal Outcome; Fibrosarcoma; Head and Neck Neoplasms; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Myxoma; Necrosis; Proton Therapy; Pyrimidines; Skin Ulcer; Soft Tissue Infections; Sulfonamides; Tomography, X-Ray Computed | 2017 |
Monoamine carboxylate transporters are involved in BI-1-associated cancer metastasis in HT1080 colon fibrosarcoma cells.
Topics: Apoptosis Regulatory Proteins; Cell Death; Cell Line, Tumor; Colonic Neoplasms; Extracellular Space; Fibrosarcoma; Gene Expression; Homeostasis; Humans; Hydrogen-Ion Concentration; Indazoles; Membrane Proteins; Neoplasm Metastasis; Sodium-Hydrogen Exchangers; Vesicular Monoamine Transport Proteins | 2011 |
Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Drug Synergism; Fibrosarcoma; HeLa Cells; Humans; Hyperthermia, Induced; Indazoles; Methylcholanthrene; Mice; Mice, Inbred BALB C; Pyrazoles | 1984 |
Radiosensitization of Meth-A fibrosarcoma in mice by Lonidamine.
Topics: Animals; Antineoplastic Agents; Fibrosarcoma; Indazoles; Male; Methylcholanthrene; Mice; Mice, Inbred BALB C; Pyrazoles; Radiation Tolerance; Time Factors | 1984 |
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Synergism; Female; Fibrosarcoma; Humans; Indazoles; Male; Mice; Mice, Inbred C3H; Novobiocin; Topotecan; Tumor Cells, Cultured | 1993 |
Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Combined Modality Therapy; Fibrosarcoma; Fluorouracil; Hyperthermia, Induced; Indazoles; Male; Mice; Mice, Inbred C3H; Neoplasms, Radiation-Induced; Sarcoma, Experimental | 1991 |
Modulation of alkylating agents by lonidamine in vivo.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bone Marrow; Cell Survival; Cisplatin; Cyclophosphamide; Drug Interactions; Fibrosarcoma; Granulocytes; Indazoles; Macrophages; Male; Mice; Mice, Inbred C3H; Mice, Inbred Strains; Thiotepa; Tumor Cells, Cultured | 1991 |
Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bone Marrow; Carbon Dioxide; Cell Survival; Colony-Forming Units Assay; Drug Combinations; Drug Interactions; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Fibrosarcoma; Fluorocarbons; Hydroxyethyl Starch Derivatives; Indazoles; Male; Mice; Oxygen; Pentoxifylline | 1991 |
Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Carmustine; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Fibrosarcoma; Humans; Indazoles; Mammary Neoplasms, Animal; Mice; Organoplatinum Compounds; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1991 |
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Fibrosarcoma; Hematopoietic Stem Cells; Indazoles; Male; Melphalan; Mice; Mice, Inbred C3H; Pentoxifylline; Sarcoma, Experimental | 1991 |
Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cisplatin; Drug Interactions; Drug Screening Assays, Antitumor; Fibrosarcoma; Humans; Indazoles; Kinetics; Mice; Neoplasms, Radiation-Induced | 1990 |